

SUPPLEMENTARY DATA

Table S1. Additional baseline characteristics according to type of infarction and treatment allocation

	STEMI		NSTEMI	
	Beta-blocker	No beta-blocker	Beta-blocker	No beta-blocker
	n = 2146	n = 2150	n = 2061	n = 2081
<i>Laboratory data</i>				
Creatinine prior to discharge \pm mg/dL	0.9 \pm 0.3	0.9 \pm 0.5	0.9 \pm 0.3	0.9 \pm 0.
eGFR \pm mL/min/1.73 m ²	91.0 \pm 18.0	91.5 \pm 1 8.2	88.3 \pm 18.8	88.5 \pm 18.5
Hemoglobin prior to discharge, \pm g/dL	14.1 \pm 1.6	14.2 \pm 1.7	14.3 \pm 1.7	14.2 \pm 1.7
LDL cholesterol at discharge \pm mg/dL)	13.7 \pm 39.0	112.1 \pm 39.4	109.6 \pm 42.1	109.1 \pm 40.1
<i>ECG and blood pressure at randomization</i>				
Atrial fibrillation	7 (0.4)	9 (0.5)	29 (1.7)	19 (1.1)
Heart rate at discharge, bpm	67.5 \pm 10.6	68.8 \pm 11.4	67.6 \pm 11.1	68.3 \pm 11.4
SBP at discharge \pm mmHg	118.7 \pm 15.1	119.5 \pm 14.0	122.2 \pm 16.3	123.8 \pm 15.
DBP at discharge \pm mmHg	71.5 \pm 9.8	72.5 \pm 9.5	72.8 \pm 9.2	73.6 \pm 9.8

The data are expressed as No.(%) or mean \pm standard deviation.

Table S2. Summary of clinical events

	STEMI		NSTEMI	
	Beta-blocker	No beta-blocker	Beta-blocker	No beta-blocker
	No. patients experiencing event ±total no. events)			
Primary endpoint				
<i>All-cause death, nonfatal reinfarction and heart failure admission</i>	149 ±168	119 ±132	167 ±192	188 ±238)
Secondary endpoints				
<i>All-cause death</i>	77	57	84	96
Cardiac death	28	20	37	37
Noncardiac death	49	37	47	59
<i>Nonfatal reinfarction</i>	70 ± 76	56 ± 61	73 ± 78	87 ±104)
<i>Heart failure admission</i>	13 ± 15	11 ± 13	26 ± 30	33 ±38)
<i>Sustained ventricular tachycardia</i>	2 ± 2	1 ± 1	1 ± 1	1 ±2)
<i>Ventricular fibrillation</i>	2 ± 2	2 ± 2	1 ± 1	3 ±3)
<i>Resuscitated cardiac arrest</i>	4 ± 4	1 ± 1	0 ±0	3 ±3)
Tertiary safety endpoint				
Admission for stroke	13 ± 13	15 ± 16	24 ±2 4	10 ±11)

The data are expressed as No. (%) or mean ± standard deviation.

Table S3. Per-protocol analysis of primary, secondary and tertiary endpoints at which patients were censored at the visit a crossover is reported

	STEMI				NSTEMI				P for interaction
	N ±rate per 1000 person-years		Rate difference ± ±95%CI	HR ± 95% CI	N ±rate per 1000 person-years		Rate difference ± 95%CI	HR ± 95%CI	
	Beta-blocker	No beta-blocker			Beta-blocker	No beta-blocker			
Primary endpoint									
All-cause death, nonfatal reinfarction and heart failure admission	130 ±20.1	100 ±15.9	4.12 ±0.53, 8.78	1.26 ±0.97, 1.64	148 ±24.1	160 ±27.1	-±.04 ±-8.76, 2.68	0.89 ±0.71, 1.11	0.046
Secondary endpoints									
All-cause death	70 ±10.6	47 ±7.4	3.18 ± 0.09, 6.46	1.43 ±0.99, 2.07	68 ±10.8	75 ±12.6	-1.75 ±-5.58, 2.09	0.86 ±0.62, 1.20	0.043
Nonfatal reinfarction	60 ±9.2	48 ±7.7	1.59 ±-1.59, 4.78	1.21 ±0.83, 1.77	69 ±11.2	76 ±12.9	-1.67 ±-5.58, 2.25	0.87 ±0.63, 1.21	0.20
Heart failure admission	11 ±1.7	8 ±1.3	0.41 ±-0.91, 1.73	1.33 ±0.53, 3.30	24 ±3.8	25 ±4.2	-0.37 ±-2.62, 1.88	0.92 ±0.52, 1.61	0.50
Cardiovascular death	25 ±3.8	16 ±2.5	1.26 ±-0.67, 3.20	1.50 ±0.80, 2.82	32 ±5.1	29 ±4.9	0.23 ±-2.27, 2.73	1.05 ±0.64, 1.74	0.38
Sustained ventricular tachycardia	2 ±0.3	1 ±0.2	0.15 ±-0.38, 0.67	1.94 ±0.18, 21.41	1 ±0.2	0 ±0.0	0.16 ±-0.15, 0.47	--	--

Ventricular fibrillation	1 ±0.2	2 ±0.3	-0.16 ±-0.69, 0.37	0.48 ±0.04, 5.33	1 ±0.2	2 ±0.3	-0.18 ±-0.74, 0.38	0.48 ±0.04, 5.24	0.99
Resuscitated cardiac arrest	3 ±0.5	1 ±0.2	0.30 ±-0.30, 0.90	2.91 ±0.30, 27.97	0 ±0.0	1 ±0.2	-0.17 ±-0.50, 0.16	--	--
Tertiary safety endpoints									
Admission for stroke	12 ±1.8	11 ±1.7	0.08 ±-1.38, 1.54	1.05 ±0.46, 2.37	23 ±3.7	9 ±1.5	2.18 ±0.37, 3.98	2.45 ±1.13, 5.29	0.14

Hazard ratios were estimated using Cox proportional hazards models with an interaction between MI type and treatment arm and estimate the effect of taking beta-blocker vs no beta-blocker. Gvalues were calculated using likelihood ratio tests.